Rxcurve
Medicare Part B payment limits Effective October 1 – December 31, 2026 Posted by CMS September 17, 2026
HCPCS Q5146 · per 10 MG

Inj, hercessi, 10 mg

Products billed under this code include Hercessi.

Payment limit per 10 MG, by effective quarter, 3Q25 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.

Products billed under Q5146

From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.

ProductLabelerNDCUnits / pkgLimit / pkg
Hercessi Accord BioPharma, Inc 69448-0015-05 15 $453.825
Hercessi Accord BioPharma, Inc 69448-0016-11 42 $1,270.71

Every quarter

QuarterPayment limitChangeBilling unitDescriptionSource file
4Q26 $30.255 −$2.205 10 MG Inj, hercessi, 10 mg v1, posted September 17, 2026
3Q26 $32.46 −$5.405 10 MG Inj, hercessi, 10 mg v1, posted September 15, 2026
2Q26 $37.865 +$0.714 10 MG Inj, hercessi, 10 mg v1, posted September 15, 2026
1Q26 $37.151 −$2.874 10 MG Inj, hercessi, 10 mg v1, posted September 15, 2026
4Q25 $40.025 −$36.156 10 MG Inj, hercessi, 10 mg v1, posted September 8, 2026
3Q25 $76.181 – 10 MG Inj, hercessi, 10 mg v1, posted March 10, 2026

“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.

CMS source files